Leerink Partnrs Issues Positive Outlook for Beigene Earnings

Beigene, Ltd. (NASDAQ:ONC) – Equities researchers at Leerink Partnrs boosted their Q2 2025 earnings estimates for shares of Beigene in a note issued to investors on Wednesday, May 7th. Leerink Partnrs analyst A. Berens now expects that the company will post earnings per share of ($0.08) for the quarter, up from their previous forecast of ($0.14). The consensus estimate for Beigene’s current full-year earnings is ($5.82) per share. Leerink Partnrs also issued estimates for Beigene’s Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.16) EPS and FY2027 earnings at $14.07 EPS.

Beigene (NASDAQ:ONC) last announced its earnings results on Wednesday, May 7th. The company reported $1.22 EPS for the quarter, topping the consensus estimate of ($0.71) by $1.93. The firm had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.12 billion. Beigene had a negative net margin of 25.94% and a negative return on equity of 25.12%.

ONC has been the topic of several other reports. JMP Securities set a $348.00 target price on shares of Beigene in a report on Friday, February 28th. Sanford C. Bernstein set a $259.00 price objective on shares of Beigene in a report on Thursday, March 13th. Macquarie lifted their price objective on shares of Beigene from $259.00 to $313.00 and gave the company an “outperform” rating in a report on Friday, February 28th. JPMorgan Chase & Co. lifted their price objective on shares of Beigene from $311.00 to $317.00 and gave the company an “overweight” rating in a report on Monday, April 21st. Finally, TD Securities reiterated a “buy” rating and issued a $334.00 price objective on shares of Beigene in a report on Thursday, April 24th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and an average price target of $319.00.

Beigene Stock Performance

Shares of ONC stock opened at $224.73 on Monday. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05. The firm has a market cap of $22.23 billion, a P/E ratio of -27.27, a P/E/G ratio of 7.73 and a beta of 0.35. The business’s 50 day moving average is $244.64. Beigene has a 52 week low of $141.31 and a 52 week high of $287.88.

Insider Activity at Beigene

In related news, COO Xiaobin Wu sold 51,921 shares of the firm’s stock in a transaction on Tuesday, April 1st. The shares were sold at an average price of $281.40, for a total value of $14,610,569.40. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Chan Henry Lee sold 1,202 shares of the firm’s stock in a transaction on Friday, February 21st. The shares were sold at an average price of $258.04, for a total transaction of $310,164.08. The disclosure for this sale can be found here. Over the last three months, insiders sold 1,146,048 shares of company stock valued at $295,198,300. 6.62% of the stock is owned by corporate insiders.

About Beigene

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.